3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
7
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
6
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Micrometastasis
1
Lymphatic Metastasis
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
24
Nivolumab
9
atezolizumab
8
Drug Therapy
6
cemiplimab
5
Immune Checkpoint Inhibitors
5
fludarabine
4
Radiotherapy
4
Paclitaxel
4
Interleukin-2
4
Cyclophosphamide
4
Docetaxel
3
fludarabine phosphate
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Radiosurgery
2
Radiation
2
Patient Reported Outcome Measures
2
Oncolytic Virotherapy
2
Ipilimumab
2
Immunotherapy
2
Gemcitabine
2
Filgrastim
2
Cisplatin
2
Cetuximab
2
Carboplatin
2
vocimagene amiretrorepvec
1
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Indocyanine Green
×
Dermatologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled